Targeting the TLR9-MyD88 pathway in the regulation of adaptive immune responses.
BACKGROUND
Toll-like receptors (TLRs) are innate immune receptors critical in the innate immune defense against invading pathogens. Recent advances also reveal a crucial role for TLRs in shaping adaptive immune responses, conferring a potential therapeutic value to their modulation in the treatment of diseases.


METHODS
The aim of this review is to discuss TLR9, the TLR9-MyD88 signaling pathway and its role in regulation of adaptive immune responses, as well as potential therapeutic implications by targeting this pathway.


RESULTS
This review shows that the TLR9-MyD88 signaling pathway plays a critical role in promoting adaptive immune responses and that modulation of this pathway may have enormous therapeutic potential in enhancing vaccine potency, controlling autoimmunity, as well as improving the outcome of viral-vector-mediated gene therapy.


CONCLUSIONS
Although TLR9 agonists have been used as adjuvants for enhancing vaccine potency, further exploitation of the TLR9-MyD88 pathway and its dynamic interaction with the immune system in vivo is needed to provide more effective therapeutic inventions in the design of vaccines for infectious diseases, allergies and cancer, in the control of autoimmunity, as well as in the improvement of viral-vector-mediated gene therapy.
Huang
Xiaopei
X
Duke University Medical Center, Department of Medicine, Durham, NC 27710, USA.
Yang
Yiping
Y
D056704:Adaptive Immunity; D000276:Adjuvants, Immunologic; D000818:Animals; D015551:Autoimmunity; D015316:Genetic Therapy; D006801:Humans; D007107:Immune System / Q000502:physiology; D007113:Immunity, Innate; D007167:Immunotherapy; D053594:Myeloid Differentiation Factor 88 / Q000378:metabolism*; D009369:Neoplasms / Q000628:therapy; D015398:Signal Transduction; D051217:Toll-Like Receptor 9 / Q000819:agonists / Q000276:immunology / Q000378:metabolism*
D000276:Adjuvants, Immunologic; D053594:Myeloid Differentiation Factor 88; D051217:Toll-Like Receptor 9